

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7332027

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ESTETRA S.P.R.L.	05/05/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NEURALIS SA
<b>Street Address:</b>	RUE SAINT-GEORGES 5
<b>City:</b>	LIÈGE
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	4000
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	9238035
<b>Patent Number:</b>	9808470
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(949)760-9502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9497600404
<b>Email:</b>	efiling@knobbe.com
<b>Correspondent Name:</b>	KNOBBE MARTENS OLSON AND BEAR, LLP
<b>Address Line 1:</b>	2040 MAIN STREET
<b>Address Line 2:</b>	14TH FLOOR
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92614
<b>ATTORNEY DOCKET NUMBER:</b>	DECL197.003APC/003P1
<b>NAME OF SUBMITTER:</b>	RAYMOND D. SMITH
<b>SIGNATURE:</b>	/Raymond D. Smith/
<b>DATE SIGNED:</b>	05/16/2022
<b>Total Attachments: 2</b>	
source=2022-05-05 Signed Assignment - DECL197.003APC and DECL197.003P1#page1.tif	
source=2022-05-05 Signed Assignment - DECL197.003APC and DECL197.003P1#page2.tif	

### ASSIGNMENT

WHEREAS, ESTETRA S.P.R.L., a corporation, having an address at Rue Saint-Georges 5, BE-4000 Liège, Belgium (hereinafter "ASSIGNOR"), represents and warrants that it is the sole owner of the entire right, title, and interest to certain new and useful improvements for patent applications and/or issued patents listed within or attached to this document (hereinafter "the Patents/Applications").

<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
9,238,035	January 19, 2016	ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
9,808,470	November 7, 2017	ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

AND WHEREAS, NEURALIS SA, a corporation, having an address at Rue Saint-Georges 5, BE-4000 Liège, Belgium (hereinafter the "ASSIGNEE"), desires to acquire or confirm ownership of the entire right, title, and interest in and to the Patents/Applications.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in and to the Patents/Applications, including: all provisional applications relating to any of the Patents/Applications; all nonprovisional applications claiming priority to aforementioned provisional(s) and/or any of the Patents/Applications, including, all divisions, continuations, continuations-in-part, and reissues thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues, and extensions thereof; all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals, and reissues thereof; and ASSIGNOR hereby authorizes and requests the Commissioner for Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR DOES HEREBY acknowledge and agree that the assigned scope of the Application and the Work includes any currently recited claims, all embodiments, and all claims supported by the Application; Assignor agrees not to contest or disparage claim scope thus supported (including in any later-filed continuing patent applications) for any claims deemed patentable by any government patent office. Assignor also agrees not to challenge the validity, including as a defense to patent infringement, of any issued patent claims resulting from or based on the Work, regardless of the scope of any such claims.

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will: communicate to said ASSIGNEE, its successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Patents/Applications; testify in any legal proceeding; assist in the preparation of any other provisional or non-provisional applications relating to the Patents/Applications or any improvements made thereto; sign/execute all lawful papers; authorize the filing of, execute, and make all rightful oaths and/or declarations in connection with the Patents/Applications including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications; and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Patents/Applications in all countries.

AND ASSIGNOR DOES HEREBY agree that if any term or provision of this agreement becomes invalid or unenforceable, the remainder shall survive unaffected.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

**Assignor (Conveying Party)**

ESTETRA S.P.R.L.

Rue Saint-Georges 5, BE-4000 Liège, Belgium

By: \_\_\_\_\_

Name: Leon Van Rompay

Title: Managing Director

Date: 05 May 2022

Witnessed by: \_\_\_\_\_

Witness Name (printed): \_\_\_\_\_

55523264